Revenue: As of FY2025 Q1, the actual value is USD 375 K.EPS: As of FY2025 Q1, the actual value is USD -0.01.<h3>Segment Revenue</h3><ul><li>Research and Other Revenue: $375,000 for the three months ended March 31, 2025, compared to $284,000 for the same period in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: The company reported a net loss of $19.3 million for the three months ended March 31, 2025, compared to $18.3 million for the same period in 2024.</li><li>Research and Development Expenses: $8.4 million for the three months ended March 31, 2025, compared to $7.9 million for the same period in 2024.</li><li>General and Administrative Expenses: $9.3 million for the three months ended March 31, 2025, compared to $8.1 million for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: - $9.4 million for the three months ended March 31, 2025, compared to - $12.4 million for the same period in 2024.</li><li>Net Cash Used in Investing Activities: - $93,000 for the three months ended March 31, 2025, compared to - $239,000 for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: $11.7 million for the three months ended March 31, 2025, compared to $12.1 million for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Convertible Notes at Fair Value: $35.9 million as of March 31, 2025, compared to $34.2 million as of December 31, 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to continue its progress on multiple fronts, including the MAA application process, manufacturing scale-up in the Sawston, UK facility, and preparations for clinical trials of DCVax-Direct.</li><li>Non-Core Business: The company is expanding its compassionate use programs and pursuing litigation against certain market makers.</li><li>Priority: The company is focused on submitting initial INDs for clinical trials of DCVax-Direct during Q2 of this year and expanding its manufacturing capabilities.</li></ul>

Northwest Biotherapeutics, Inc. | 10-Q: FY2025 Q1 Revenue: USD 375 K